During the past 3 years, the average Free Cash Flow per Share Growth Rate was 84.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 70.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Entero Therapeutics was 84.90% per year. The lowest was 17.30% per year. And the median was 46.85% per year.
Competitive Comparison of Entero Therapeutics's 3-Year FCF Growth Rate
For the Biotechnology subindustry, Entero Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entero Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entero Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Entero Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Entero Therapeutics 3-Year FCF Growth Rate Related Terms
Thank you for viewing the detailed overview of Entero Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Entero Therapeutics (Entero Therapeutics) Business Description
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTO has been successfully added to your